17.60
price up icon0.80%   0.14
after-market 시간 외 거래: 17.88 0.28 +1.59%
loading

Viatris Inc 주식(VTRS)의 최신 뉴스

pulisher
Oct 01, 2026

Why Viatris (VTRS) is a Top Value Stock for the Long-Term - Zacks Investment Research

Oct 01, 2026
pulisher
Sep 30, 2026

Viatris Facing Multiple Paths to Earnings Growth, Oppenheimer Says - Moomoo

Sep 30, 2026
pulisher
Sep 30, 2026

Net income before discontinued operations of Viatris, Inc. – HAN:VIA - TradingView

Sep 30, 2026
pulisher
Sep 29, 2026

Viatris named to Forbes' World's Best Employers list for sixth year, highlighting strong workplace culture. - Pluang

Sep 29, 2026
pulisher
Sep 29, 2026

Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year - PR Newswire

Sep 29, 2026
pulisher
Sep 29, 2026

Viatris stock hits 52-week high at 18.4 USD By Investing.com - Investing.com Australia

Sep 29, 2026
pulisher
Sep 29, 2026

Viatris stock hits 52-week high at 18.4 USD - Investing.com

Sep 29, 2026
pulisher
Sep 29, 2026

Viatris Inc Agencies, 2022 - OpenSecrets

Sep 29, 2026
pulisher
Sep 28, 2026

Viatris Inc. stock rises Monday, outperforms market - MarketWatch

Sep 28, 2026
pulisher
Sep 26, 2026

Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune

Sep 26, 2026
pulisher
Sep 26, 2026

Viatris (VTRS) Q2 2026 Earnings Call Transcript - Fortune

Sep 26, 2026
pulisher
Sep 25, 2026

Viatris Inc Agencies, 2026 - OpenSecrets

Sep 25, 2026
pulisher
Sep 25, 2026

Viatris Inc. stock rises Friday, outperforms market - MarketWatch

Sep 25, 2026
pulisher
Sep 25, 2026

Viatris sues Novo Nordisk, seeks to market generic Wegovy - Seeking Alpha

Sep 25, 2026
pulisher
Sep 25, 2026

Viatris sues Novo Nordisk over generic Wegovy patent dispute - Yahoo Finance

Sep 25, 2026
pulisher
Sep 25, 2026

Viatris sues Novo Nordisk over generic Wegovy patent dispute By Investing.com - Investing.com Canada

Sep 25, 2026
pulisher
Sep 25, 2026

Mylan asks US court to clear Wegovy generic from Novo patent claims - reuters.com

Sep 25, 2026
pulisher
Sep 25, 2026

Trump seeks to produce more generic drugs in the US - Seeking Alpha

Sep 25, 2026
pulisher
Sep 24, 2026

Is Viatris Stock Outperforming the S&P 500? - Yahoo Finance

Sep 24, 2026
pulisher
Sep 24, 2026

How Viatris Inc. (VTRS) Affects Rotational Strategy Timing - Stock Traders Daily

Sep 24, 2026
pulisher
Sep 23, 2026

Viatris (VTRS) Q4 2025 Earnings Call Transcript - fortune.com

Sep 23, 2026
pulisher
Sep 23, 2026

VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill

Sep 23, 2026
pulisher
Sep 23, 2026

Viatris, Teva initiated at Outperform at Oppenheimer - Seeking Alpha

Sep 23, 2026
pulisher
Sep 23, 2026

Oppenheimer Initiates Viatris at Outperform With $25 Price Target - marketscreener.com

Sep 23, 2026
pulisher
Sep 23, 2026

Oppenheimer initiates Viatris stock with outperform rating - Investing.com

Sep 23, 2026
pulisher
Sep 23, 2026

Oppenheimer initiates Viatris stock with outperform rating By Investing.com - Investing.com Nigeria

Sep 23, 2026
pulisher
Sep 21, 2026

Viatris Inc. (VTRS) Stock Analysis: Exploring A 10.78% Upside With Strategic Collaborations - DirectorsTalk Interviews

Sep 21, 2026
pulisher
Sep 20, 2026

Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business? - Yahoo Finance

Sep 20, 2026
pulisher
Sep 18, 2026

Viatris Inc. stock falls Friday, underperforms market - MarketWatch

Sep 18, 2026
pulisher
Sep 16, 2026

Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch

Sep 16, 2026
pulisher
Sep 16, 2026

Piper Sandler raises Viatris stock price target on patch growth - Investing.com

Sep 16, 2026
pulisher
Sep 16, 2026

Viatris receives Japan approval for sleep disorder drug Wakix - Investing.com

Sep 16, 2026
pulisher
Sep 16, 2026

Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome - PR Newswire

Sep 16, 2026
pulisher
Sep 16, 2026

Piper Sandler Adjusts Price Target on Viatris to $13 From $12, Keeps Neutral Rating - Yahoo Finance

Sep 16, 2026
pulisher
Sep 10, 2026

Viatris, Long Chau launch lipid disorder management campaign - VnExpress International

Sep 10, 2026
pulisher
Sep 10, 2026

Viatris (VTRS) Q2 Earnings Preview: What's in the Cards? - Eastern Progress

Sep 10, 2026
pulisher
Sep 09, 2026

Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive - Seeking Alpha

Sep 09, 2026
pulisher
Sep 09, 2026

VTRS - Finviz

Sep 09, 2026
pulisher
Sep 09, 2026

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress

Sep 09, 2026
pulisher
Sep 09, 2026

Leerink Partners Initiates Viatris at Outperform With $20 Price Target - marketscreener.com

Sep 09, 2026
pulisher
Sep 08, 2026

Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch

Sep 08, 2026
pulisher
Sep 08, 2026

Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - Moomoo

Sep 08, 2026
pulisher
Sep 08, 2026

Viatris gets 11% passive stake disclosed by FMR | VTRS SEC FilingForm SCHEDULE 13G/A - Stock Titan

Sep 08, 2026
pulisher
Sep 08, 2026

Argus Research Upgrades Viatris(VTRS.US) to Buy Rating, Announces Target Price $20 - Moomoo

Sep 08, 2026
pulisher
Sep 07, 2026

Viatris Inc. (VTRS) Stock Analysis: Evaluating the Healthcare Giant’s 9.60% Potential Upside for Investors - DirectorsTalk Interviews

Sep 07, 2026
pulisher
Aug 31, 2026

Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris - Yahoo Finance

Aug 31, 2026
pulisher
Aug 31, 2026

Viatris Inc. (VTRS) Stock Analysis: Exploring Its 13% Upside Potential And Dividend Appeal - DirectorsTalk Interviews

Aug 31, 2026
pulisher
Aug 29, 2026

Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough? - Yahoo Finance

Aug 29, 2026
pulisher
Aug 28, 2026

Viatris Inc (VTRS) Shares Fall 3.3% -- GF Value Says Still Overv - GuruFocus

Aug 28, 2026
pulisher
Aug 27, 2026

Viatris Inc (VTRS): A Closer Look Behind a 60 GF Score - GuruFocus

Aug 27, 2026
pulisher
Aug 25, 2026

Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch

Aug 25, 2026
$541.70
price down icon 5.19%
$143.18
price up icon 1.76%
ZTS ZTS
$69.69
price up icon 0.85%
$22.14
price up icon 1.70%
RDY RDY
$12.25
price up icon 0.00%
자본화:     |  볼륨(24시간):